5Gerstin HC. Glucose: A continuous risk factor for cardiovasular disease Diabet Med, 1997,14( Suppl 3 ) :25.
二级参考文献18
1[1]Feher M, Elkeles R.Lipid modification and coronary heart disease in type 2 diabetes:different from the general population.Heart,1999,81:10-11.
2[2]Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adults Treatment Panel III).JAMA,2001,285:2486-2497.
3[3]Holman R. The UKPDS: implications for the dyslipidaemic patient. Acta Diabetol,2001,38: S9-14.
4[4]Taskinen MR, Smith U. Lipid disorders in NIDDM: implications for treatment. Journal of Internal Medicine,1998,244:361-370.
5[5]Barnett AH.Dyslipidaemia in diabetes-A GP guide.Practitioner,2002,246:120-123.
7[7]Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med,1996,335:1001-1009.
8[8]Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Survival Study (4S). Lancet,1994,344:1383-1389.
9[9]Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Eng J Med,1998,339:1349-1357.
10[10]MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.Lancet,2002,360(9326):7-22.
